The overall aim of the ViVac project is to develop and to show safety and efficacy for a new innovative carbohydrate (chitosan) based adjuvant -Viscogel –to be used both in prophylactic and therapeutic vaccination. Three SME participants will contribute with their specific technologies: the unique Viscogel technology, a specific type of cationic peptides with cell-penetrating capacity (LTX) and a ...